Last reviewed · How we verify

NCT05150821

Impact of Covid-19 in the Emergency Department

Completed Last updated 25 August 2023
What this trial tests

trial in COVID-19 in 599 participants. Completed in 1 July 2023.

Timeline
1 September 2020
Primary endpoint
1 July 2023
1 July 2023

Quick facts

Lead sponsorDr. Panagiota Manava
StatusCompleted
Study typeOBSERVATIONAL
Enrollment599
Start date1 September 2020
Primary completion1 July 2023
Estimated completion1 July 2023
Sites1 location across Germany

Conditions studied

Sponsor

Dr. Panagiota Manava

Who can join

Eligibility, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To investigate the effects of lockdown in the Emergency Department in a tertiary health care hospital, Nuremberg, Germany.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for COVID-19

Currently open trials in the same condition.

Other Dr. Panagiota Manava trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05150821.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing